ClinicalTrials.gg
CompletedNCT07121361RASMAUpdated Aug 13, 2025

Effectiveness of Recurrent Aphthous Stomatitis Mouthwash System for the Treatment of Oral Ulcers

An interventional study of Mouthwash Product and Control in Recurrent Aphthous Ulcer and Recurrent Aphthous Stomatitis, sponsored by G. d'Annunzio University. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by G. d'Annunzio University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Nov 2023, registered Aug 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

The purpose of the present research is to evaluate the efficacy of a gel formulation for a total treatment of 14 days for the treatment of traumatic or aphthous oral ulcers.

Read the detailed description

Primary Objective

Evaluation of the clinical efficacy of the treatment using the following scores and clinical parameters:

Pain intensity, measured using the VAS (Visual Analogue Scale), consisting of a 10 cm line, where 0 indicates no pain and 10 indicates intense pain.

Size of each ulcer.

Secondary Objectives

Evaluation of the following scores and clinical parameters:

  1. Registration of the superficial temperature of the mucous membranes using Infrared Thermography.
  2. Ulcer Severity Score (USS).
02

Conditions studied

  • Recurrent Aphthous Ulcer
  • Recurrent Aphthous Stomatitis

Keywords

  • Ulcers
  • Oral Hygiene
  • Oral care
03

In context

Stomatitis, Aphthous

63 studies on the registry are indexed under Stomatitis, Aphthous; 17 are open to participants now.

This study's enrollment of 60 is above the median of 41 across 54 interventional studies indexed under Stomatitis, Aphthous.

Browse Stomatitis, Aphthous studies →

Lead sponsor

G. d'Annunzio University is the lead sponsor of 67 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with at least one well-defined oral ulcer.
  • Patients with no cognitive disorders able to provide mouthwash treatment independently

Exclusion criteria

Exclusion Criteria:

  • Proven intolerance or allergy to the product.
  • Patients with a hematological deficit such as anemia, iron deficiency, vitamin B12 and/or folic acid
  • No systemic diseases including ulcerative colitis, Crohn's disease, Behçet's syndrome with recurrent aphthous lesions; alcohol and tobacco consumption;
  • No history of allergies;
  • No previously treatment of oral ulcers with topical , vitamins, antibiotics, antihistamines, oral retinoids, or immunomodulatory agents within three months prior to entering the study;
  • No non-steroidal anti-inflammatory drugs or mouthwash administrations for the treatment of the ulcer within 72 hours before entering the study.
  • Pregnants or breastfeeding patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    DNA mouthwash

    The compound is characterized by a formulation that ensures effective action on the film-forming component. The presence of DNA fractions increases the viscosity of the solutions and increases the hydration of the mucous membranes with a consequent improvement in trophism for oral ulcers. The treatment indications are to delay and prevent oral ulcers and the formation of bacterial plaque; prevent irritation of the gums and oral cavity, even in wearers of prostheses and orthodontic implants accompanied by problems with dental support structures; after tooth extraction; before and after any dental surgery. The patients will be instructed to rinse the mouth and ulcers with the mouthwash twice a day after oral hygiene for 14 days

    Device: Mouthwash Product

  • Placebo comparator
    Placebo mouthwash

    The placebo will be deprived by all components. The patients will be instructed to rinse the mouth and ulcers with the mouthwash twice a day after oral hygiene for 14 days

    Device: Control

Interventions

  • DeviceMouthwash Product

    DNA mouthwash

  • DeviceControl

    Placebo mouthwash

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Pain intensity, measured using the VAS (Visual Analogue Scale), consisting of a 10 cm line, where 0 indicates no pain and 10 indicates intense pain.

    Time frame: 14 days

  2. Ulcers Dimensions

    Size of each ulcer measured through a sheet of clear plastic will be applied directly to the ulcer by tracing the circumference of the ulcer and then placed on a graph paper and the number of mm2 units included within the drawn area will be counted.

    Time frame: 14 days

07

Study locations

1 site
  • University of Chieti- Department of Innovative Technology in Medicine and Dentistry
    Chieti, Abruzzo 66100, Italy
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07121361
Lead sponsor
G. d'Annunzio University
Responsible party
Felice Lorusso (Senior Researcher, Department of Innovative Technologies in Medicine and Dentistry, University "G.d'Annunzio" of Chieti-Pescara, G. d'Annunzio University) — Principal investigator
First posted
Aug 13, 2025
Start date
Nov 28, 2023
Primary completion
Jan 10, 2024
Completion
Feb 24, 2024
Last update
Aug 13, 2025

Study contacts

Prof. Antonio Scarano Antonio Scarano, MD DDS
study director · Department of Innovative Technology in Medicine and Dentistry

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion